COO Shaw Timothy Buys Nearly 10 Million MARIMED Shares Amid Stock Decline—Insider Confidence Signals Possible Rebound

Insider Activity at MARIMED INC. – A Window into the Company’s Direction

Current Transaction Snapshot On October 15, 2026, Chief Operating Officer Shaw Timothy executed a large buy of 42,657 common shares, paying only $0.06 per share—the same price at which the stock traded that day. The purchase was part of the vesting of a previously granted RSU award, converting the units into ordinary shares at a one‑to‑one ratio. At the same time, Shaw sold 12,520 shares to satisfy tax withholding obligations on the RSU vesting, a routine transaction that leaves the overall holding unchanged. The net result is an increase of 42,657 shares in his direct ownership, bringing his post‑transaction position to 9,503,779 shares (≈ 3.98 % of the outstanding shares).

Implications for Investors The timing of the purchase is telling. The share price was down nearly 18 % in the week prior and had fallen 36 % over the month, reflecting a bearish trend for this OTC‑listed, specialty‑pharma company. Yet Shaw’s action—buying during a trough—signals confidence in a rebound or at least stability. Insider buying in a declining market often indicates that executives believe the stock is undervalued or that they are committed to the long‑term strategy. The sale of RSUs to cover taxes is standard; it does not dilute ownership or reveal a lack of conviction.

Broader Insider Activity Context MARIMED’s senior leadership has been active this quarter. CFO Pinho Mario and CEO Levine Jon R each made multiple trades, including significant purchases of common stock (e.g., Pinho’s 38,282‑share buy on 10 15 and Levine’s 30,625‑share buy on the same day). The Commercial Officer Crandall Ryan also bought 32,812 shares, offset by a 9,631‑share sale. This pattern of buying during price dips, coupled with occasional RSU sales to cover taxes, suggests a coordinated approach to building long‑term equity positions rather than short‑term speculation.

Shaw Timothy – A Profile Through the Numbers Examining Shaw’s historic transactions reveals a consistent theme: he routinely sells RSUs upon vesting and then re‑buys the corresponding common shares. Since April 2026, he has executed at least 24 trades, with a net buying bias of roughly 70 % common shares and 30 % RSUs. He maintains a substantial 2 million‑share trust holding, indicating a long‑term commitment to the company’s success. The pattern of buying during downward trends—such as the 2026‑09‑01 purchase of 65,000 shares when the price was $0.077—underscores a willingness to add to his position when the market is depressed.

Looking Ahead MARIMED’s fundamentals are uneven: a negative price‑earnings ratio, significant volatility, and a small market cap of $23.8 M. Yet insider buying, especially by the COO, signals that leadership believes the company’s cannabis‑focused business model will recover as regulatory and market conditions improve. For investors, Shaw’s latest purchase is a subtle endorsement that could warrant closer scrutiny of MARIMED’s upcoming clinical or expansion announcements. As the company navigates a challenging sector, continued insider conviction may serve as a barometer of internal confidence, offering a useful, albeit imperfect, signal for long‑term positioning.